Should You Buy The Dogs Of The FTSE For 2015? Royal Dutch Shell Plc, GlaxoSmithKline plc, Standard Chartered PLC, Direct Line Insurance Group PLC And Admiral Group plc

Royal Dutch Shell Plc (LON:RDSB), GlaxoSmithKline plc (LON:GSK), Standard Chartered PLC (LON:STAN), Direct Line Insurance Group PLC (LON:DLG) and Admiral Group plc (LON:ADM) could all beat the market in 2015.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

This is the second part of my two-part series looking at the 10 FTSE 100 stocks that qualify for a UK version of the popular Dogs of the Dow high-yield investment strategy.

The Dogs strategy involves buying the 10 highest-yielding stocks in the index at the start of the year, and then selling them at the end of the year. In the US, the Dogs strategy has beaten the Dow in two of the last three years.

Here are the final five 2015 Dog stocks from the FTSE 100 (if you missed the first five stocks, you can catch up here):

Company

2015 prospective yield

Royal Dutch Shell (LSE: RDSB)

5.9%

GlaxoSmithKline (LSE: GSK)

5.9%

Standard Chartered (LSE: STAN)

6.0%

Direct Line Insurance Group (LSE: DLG)

7.4%

Admiral Group (LSE: ADM)

6.9%

Shell

No-one quite knows how the oil market will behave next year.

However, Shell should be able to afford to ride out the storm, thanks to its huge scale, large gas business and low debt levels.

Although cash flow could come under pressure next year, the firm’s forecast P/E of 9.8 suggests to me that Shell remains a safe income buy.

GlaxoSmithKline

Allegations of bribery and corruption, patent expiries, and falling profits.

It’s been a poor year for Glaxo, but this has left the UK’s largest pharmaceutical firm trading with a prospective yield of nearly 6% and a planned 82p per share capital return in 2015.

Glaxo remains in my portfolio, and on my buy list.

Standard Chartered

Shares in Asia-focused Standard Chartered have fallen by around 35% this year, amid a constant run of downgraded forecasts.

As a result, the bank’s shares trade on a 2015 forecast P/E of just 8.1, which prices in a lot of bad news, in my view. A prospective yield of around 5.9% should also reward patient investors.

Direct Line

Direct Line makes it into the Dogs of the FTSE thanks to a generous special dividend policy, which gives the firm’s shares a prospective yield of 7.4%, the highest in this group.

The fall in motor insurance premiums does seem to be slowing, so 2015 could be a reasonable year for Direct Line.

Admiral

As with Direct Line, it’s important to remember that these insurers’ generous yields are driven by special dividends, which are currently being paid every year, but may not be in the future.

That aside, Admiral’s 2015 forecast P/E of 14.2 reflects the fact that earnings per share are expected to fall by around 8% next year, raising the risk that dividend growth could also stall.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head owns shares in Royal Dutch Shell and GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

£17,000 in savings? Here’s how I’d target a weighty passive income

Funnelling any spare savings towards building a passive income is certainly a smart idea, but how to find the right…

Read more »

Investing Articles

Why is this FTSE 250 giant up 35% in two weeks?

Seeing a share price soaring can often be a reason to be cautious, but I still think there's a lot…

Read more »

Light bulb with growing tree.
Investing Articles

Is there still time to snap up this ex-penny stock in May?

A penny stock no more but a promising low-cap company nonetheless. Our writer examines the growth prospects of this sustainable…

Read more »

Close-up of British bank notes
Investing Articles

Here’s how I’d target a £1,890 second income by investing £35 a week

Christopher Ruane explains how, for a fiver a day, he'd aim to build a second income of almost £1,900 in…

Read more »

Dividend Shares

£5k in savings? Here’s how I’d try to turn it into £414 of monthly passive income

Jon Smith explains how he'd use both dividend and growth shares to help him take a lump sum of £5k…

Read more »

Fans of Warren Buffett taking his photo
Investing Articles

Warren Buffett’s sitting on $189bn in cash. What’s this telling us?

Legendary stock market investor Warren Buffett's currently sitting on a cash pile bigger than most FTSE 100 companies. Is this…

Read more »

Typical street lined with terraced houses and parked cars
Dividend Shares

Here’s how much income I’d make if I invested all my ISA in Taylor Wimpey shares

Jon Smith explains why researching Taylor Wimpey shares could be a good move, based on historical dividend payments and the…

Read more »

Value Shares

Why Marks and Spencer could be one of the UK’s best value stocks right now

With a low valuation and a rising dividend payout, Marks and Spencer could be a great value stock to consider,…

Read more »